ALK POSITIVE LUNG CANCER (UK)
We provide a support network in the UK for patients with ALK-positive lung cancer and their families. We provide advice and information so that patients can be empowered to have meaningful conversations with their healthcare professionals. We advocate on their behalf at a national level so that patients receive a high level of care wherever they live in the UK
Financial health, per its FY2024 accounts
The accounts state that the charity held unrestricted reserves of £177,023 at the end of the year, representing a year-on-year increase of £68,000 driven by increased fundraising and donations. The trustees note uncertainty regarding future conference funding and the need to employ a part-time CEO, indicating an expectation to draw on these balances in future years. The charity describes itself as risk averse, ensuring sufficient funds are held before committing to expenditure.
What the accounts disclose
“With uncertainty about funding of future conferences and the need to employ a part-time CEO, it is expected that we will draw on balances in future years.”
Trustees
- Debra Louise Montaguechair
- Andrew Thomson McKay
- Geoffrey Paul Otterman
- Graham Herbert Lavender
- Rachel Rowan
- Traceydawn White
Income and spending
| Financial year end | Income | Spending |
|---|---|---|
| 31/12/2024 | £220k | £153k |
| 31/12/2023 | £183k | £202k |
| 31/12/2022 | £131k | £115k |
| 31/12/2021 | £164k | £108k |
| 31/12/2020 | £56k | £24k |
Common questions
Is ALK POSITIVE LUNG CANCER (UK) financially healthy?
Per its FY2024 accounts: The accounts state that the charity held unrestricted reserves of £177,023 at the end of the year, representing a year-on-year increase of £68,000 driven by increased fundraising and donations. The trustees note uncertainty regarding future conference funding and the need to employ a part-time CEO, indicating an expectation to draw on these balances in future years. The charity describes itself as risk averse, ensuring sufficient funds are held before committing to expenditure. Its FY2024 accounts were independently examined.